All Posts By

Allison Sit

Nov 14
Love0

Patient Buzz: Skin Care After GLP-1 Weight Loss

By Patient Care

skin care after GLP-1 weight loss

GLP-1 agonists are a popular method of losing weight, which is leading to patient questions about skin care after GLP-1 weight loss. In this Next Steps in Derm Patient Buzz, Heather Woolery-Lloyd, MD, FAAD, outlines skincare ingredients that can address skin laxity and textural changes from losing a significant amount of weight. She also addresses in-office procedures and when to refer a patient to a plastic surgeon. Find out her approach with patients who are experiencing significant weight loss and why it’s important to set realistic expectations with patients.

GLP-1 agonists are increasingly used by dermatologists to address comorbidities from inflammatory skin diseases. For more on their dermatologic use, attend the ODAC session, “GLP-1 Agonists in Cutaneous Medicine: Rapid-Fire Insights on Comorbidities, Safety, and Aesthetic Considerations – Panel Discussion”. Register today!

Nov 05
Love0

Improve Quality of Life in Patients With Hyperhidrosis

By Medical Dermatology

hyperhidrosis

Hyperhidrosis affects nearly 400 million people worldwide, yet it’s often misunderstood and underdiagnosed. In fact, 27% of adults never receive a diagnosis, according to the International Hyperhidrosis Society. The condition greatly impacts a person’s quality of life: People with excessive sweating face nearly three times the risk of anxiety and depression.

November is Hyperhidrosis Awareness Month. Let’s bring excessive sweating out of hiding and help people find understanding and treatment.

Join us for the ODAC Pre-Conference Virtual Symposium on Tuesday, November 11, where dermatologist Dr. Angela Lamb will share strategies and new tools to improve quality of life in patients with excessive sweating. You’ll also experience case-based sessions on chronic itch, hidradenitis suppurativa, and pediatric alopecia areata. Registration is complimentary – plus you can earn CME!

We hope to see you at this interactive event that’s sure to provide you with practical takeaways you can immediately apply in clinic.

Improve your knowledge and provide hyperhidrosis patients with hope and healing.

Oct 29
Love0

Growing a Dermatology Practice: ODAC Interview

By ODAC Sessions

growing a dermatology practice

A service-oriented culture can help grow a dermatology practice, according to ODAC faculty Robyn Siperstein, MD, FAAD. Dr. Siperstein credits her workplace culture for her practice’s expansion to more than 100 staff members at two locations.

Check out this interview with Next Steps in Derm from ODAC 2025 where Dr. Siperstein shares her early leadership lessons and how this culture permeates her office from the top down. Go to school on Dr. Siperstein’s signature moves in growing a dermatology practice through service. Plus learn how to make each patient interaction one that expresses value.

Are you a wannabe practice owner? Register for ODAC 2026 and attend Dr. Ronda S. Farah’s session on what it takes to open a dermatology practice.

Oct 24
Love0

Vulvar Dermatoses: ODAC Pearls from Dr. Christina Kraus

By ODAC Sessions

vulvar dermatoses

At the 2025 ODAC Dermatology Conference, Christina Kraus, MD, FAAD, reviewed systemic treatment options for refractory vulvar inflammatory dermatoses, such as lichen sclerosus (LS), lichen planus (LP), and lichen simplex chronicus (LSC). While most cases respond to potent topical corticosteroids, systemics may be needed for severe or pre-scarring disease, recalcitrant symptoms, or when topical use is limited by side effects or patient preference.

Key takeaways:

  • When to consider systemics: severe/refractory disease, extragenital involvement, prevention of scarring, poor quality of life, or steroid-sparing needs.
  • Common agents: oral retinoids, methotrexate, mycophenolate mofetil, adalimumab; systemic steroids mainly for short-term use.
  • Emerging options: IL-23 inhibitors and JAK inhibitors show promise but require further study.
  • Condition-specific notes:
    • LS: maintenance therapy critical to prevent scarring/malignancy.
    • LP: erosive type often requires systemic therapy; overlap with LS should be considered.
    • LSC: no scarring risk but major quality-of-life impact; systemic immunosuppressants, dupilumab, or neuropathic agents may help.
  • Approach: shared decision-making, patient counseling, monitoring, and collaboration with gynecology/rheumatology as appropriate.

Bottom line: Systemic agents can expand therapeutic options for vulvar dermatoses when topicals fail, but careful patient selection, counseling, and ongoing study of newer therapies are essential.

This session summary was written by Kala Hurst, DO, and published on Next Steps in Derm.

Register for ODAC 2026 for more medical dermatology updates.

Oct 17
Love0

What’s New in Rosacea: Interview with Dr. Adam Friedman

By ODAC Sessions

rosacea

ODAC Co-Chair Adam Friedman, MD, FAAD, says he’s changed the way he approaches rosacea due to some nuances in recently published studies.

Watch this Next Steps in Derm video interview with Dr. Friedman from ODAC 2025 where he addresses what’s new in the understanding of rosacea triggers. Does current research support the longstanding guidance to avoid coffee? Plus learn Dr. Friedman’s top strategies for managing rosacea and find out about three recently FDA-approved rosacea therapies.

Don’t miss Dr. Friedman’s rosacea session at ODAC 2026 where he’ll address more new developments and practical approaches. Register today!

Oct 07
Love0

Patient Buzz: Eczema & Mental Health

By Medical Dermatology

eczema and mental health

In recognition of October as Eczema Awareness Month, we consider the mental health implications of eczema. In this Next Steps in Derm Patient Buzz, dermatologist and clinical psychologist Richard Fried, MD, PhD, shares what clinicians should know about eczema’s mental health impact.

Learn what mental health symptoms are common in eczema patients and how to broach the subject in your patient interactions. Find out how Dr. Fried directs his patients who are looking for help in improving their eczema-related mental health. 

Register for ODAC 2026 for the latest guidance in treating eczema and other inflammatory skin conditions.

Sep 29
Love0

The Dermatology Digest: ODAC 2025 Coverage on Prurigo Nodularis

By Media Coverage

prurigo nodularis

ODAC Conference Co-Chair Adam Friedman, MD, FAAD, spoke with The Dermatology Digest about his ODAC 2025 presentation on prurigo nodularis.

Learn what’s new in the understanding of the condition and what to consider in a differential diagnosis. Hear Dr. Friedman’s insight on the significant burden prurigo nodularis places upon patients. (It may shock you!) Plus find out about FDA-approved therapies and the two therapeutic pathways to consider combining in your treatment plan.

For more on prurigo nodularis, register for ODAC 2026 and attend Dr. Friedman’s lecture, “Prurigo Nodularis & Other Pruritic Problems”.

Sep 23
Love0

Secukinumab Therapeutic Cheat Sheet

By Medical Dermatology

secukinumab

ODAC shares practical, clinically relevant updates in medical dermatology. Our partner Next Steps in Derm shares this new cheat sheet for prescribing and managing patients on secukinumab.

Learn secukinumab’s mechanism of action and dermatologic uses. Know side effects, and warnings and precautions. Plus find out what baseline lab monitoring you should order.

The Secukinumab Therapeutic Cheat Sheet is available online and in a downloadable and printable PDF.

Register for ODAC and learn the latest in treating psoriasis, psoriatic arthritis, hidradenitis suppurativa, and other dermatologic conditions where secukinumab is a treatment option.

Sep 17
Love0

Surgical Reconstruction Pearls

By ODAC Sessions

surgical reconstruction pearls

Think outside the box. That’s the direction of dermatologic surgeon Timothy C. Flynn, MD, FAAD, to dermatologists conducting surgical reconstruction.

Watch this Next Steps in Derm video interview with Dr. Flynn from ODAC 2025 where he shares questions dermatologists should ask when addressing a wound. Find out why considering shadows and highlights is important for positive outcomes and which aspects of beauty to consider when conducting surgical reconstruction.

Register for ODAC 2026 for more surgical dermatology pearls.

Sep 12
Love0

Neuromodulator Complications: ODAC Pearls with Dr. Watchmaker

By ODAC Sessions, Uncategorized

neuromodulator complications

At the 2025 ODAC Dermatology Conference, Jacqueline Watchmaker, MD, shared how to assess and manage neuromodulator complications. Here are some highlights from her session:

  • With heavy eyelids, Dr. Watchmaker says it’s crucial to determine whether the issue lies with the brow or the eyelid itself.
  • Brow ptosis is caused by too many units overall in the frontalis, too many units too low or lateral in the frontalis, or diffusion of neuromodulator from the glabellar complex to the lower frontalis.
  • Watchmaker suggests adding units to the depressor muscles (procerus/corrugators/orbicularis oculi) to help lift the brow. Also, with time, she says the neurotoxin’s effects will naturally fade, resolving the brow ptosis without intervention.
  • A “crooked smile” effect can happen when inadvertently injecting the depressor labii inferioris (DLI) muscle. Injecting one unit of the neuromodulator into the contralateral DLI muscle will lessen the effect naturally in a few weeks.
  • A “shelf” appearance under the eye occurs when too much neuromodulator is injected into the orbicularis oculi muscle. This may be prevented by using only 1-2 units for the most inferior injection.
  • Patients also may notice more prominent “sleep lines” post-injection. She recommends patients wear hydrocolloid bandages at night if the lines are bothersome.
  • Watchmaker also debunks several myths that are often shared with patients after neuromodulator injections, including not bending down or lying down for four hours post-injection, or not working out for 24 hours.
  • Watchmaker says there is limited data regarding whether exercising facial muscles or taking oral zinc help prolong a neuromodulator’s duration.

This session summary was written by Vixey Silva, DO, and published on Next Steps in Derm.

Register for ODAC 2026 for more pearls on preventing and managing complications.

 

Close Menu